annb0t
Top 20
Immutep Limited
Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022 Improved Overall Response Rate (ORR) of 37.3% (intent to treat, 28/75 patients) as assessed by local read based on 75 patients and compared to 36.1% at ASCO 2021 Responses observed in all PD-L1 subgroups with 32% ORR in patients with no or low PD-L1 (TPS < 50%) Improved Disease Control Rate of...
>>> Read more: Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022 Improved Overall Response Rate (ORR) of 37.3% (intent to treat, 28/75 patients) as assessed by local read based on 75 patients and compared to 36.1% at ASCO 2021 Responses observed in all PD-L1 subgroups with 32% ORR in patients with no or low PD-L1 (TPS < 50%) Improved Disease Control Rate of...
>>> Read more: Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
